Erudio Healtherudio.com
Sponsor
Innovent Biologics (Suzhou) trials: what clinicians said in public
An HCP commentary report on 1 clinical trial sponsored by Innovent Biologics (Suzhou): G-HOPE-001. It covers what clinicians said in public about one trial, on podcasts, videos and posts, every statement linked to its source. Below them, 2 more trials with public commentary and no report yet.
Listed by lead sponsor as registered on ClinicalTrials.gov (Innovent Biologics (Suzhou) Co. Ltd.). A trial led by a partner or a research group is on that sponsor's page. Only trials with public clinician commentary found are listed, not every trial the sponsor runs.
| Trial | Indication | Phase | Statements | Sources | Size | Checked | Preview |
|---|---|---|---|---|---|---|---|
| G-HOPE-001 NCT06238843 · Innovent Biologics (Suzhou) Co. Ltd. | CLDN18.2-positive HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma | Phase 3 | 116 | 29 | Focused | Nov 13, 2026 | Preview |
| No report yetTrials with public commentary we haven't built a report for. Size is an estimate of the verified statements the commentary we've indexed so far will yield; final coverage is set when we build the report, within 24 hours of your confirmed order. You never pay more than quoted: a report delivered at a smaller size costs that size's price. Some can also be requested as a free preview. | |||||||
| ORIENT-31 NCT03802240 · Innovent Biologics (Suzhou) Co. Ltd. DeepView → | EGFR-mutated non-squamous NSCLC after EGFR-TKI treatment failure | Phase 3 | Deep | View | |||
| ORIENT-32 NCT03794440 · Innovent Biologics (Suzhou) Co. Ltd. FocusedView → | first-line unresectable hepatocellular carcinoma | Phase 2/Phase 3 | Focused | View | |||